Prospects for a MERS-CoV spike vaccine
- PMID: 30058403
- PMCID: PMC6355461
- DOI: 10.1080/14760584.2018.1506702
Prospects for a MERS-CoV spike vaccine
Abstract
Introduction: Six years have passed since Middle East respiratory syndrome (MERS) coronavirus (MERS-CoV), a newly emerging infectious virus, was first reported in 2012. Although MERS-CoV has had a consistently high mortality rate in humans, no vaccines have been approved to prevent MERS-CoV infection in humans. MERS-CoV spike (S) protein is a key target for development of MERS vaccines.
Areas covered: In this review, we illustrate the structure and function of S protein as a vaccine target, describe available animal models for evaluating MERS vaccines, and summarize recent progress on MERS-CoV S-based vaccines, focusing on their ability to elicit antibody and/or cellular immune responses, neutralizing antibodies, and protection against MERS-CoV infection in different models. Prospects for future MERS-CoV S-based vaccines are discussed.
Expert commentary: The majority of MERS vaccines under development are based on MERS-CoV S protein, including full-length S, S1, and receptor-binding domain (RBD). While it is essential to evaluate the safety of full-length S and S1-based MERS vaccines, further improvement of the efficacy of RBD-based vaccines using novel strategies would be necessary. Overall, this review provides informative guidance for designing and developing safe and effective MERS vaccines based on viral S protein.
Keywords: MERS; MERS-CoV; immune responses; neutralizing antibodies; protection; receptor-binding domain; spike protein; vaccine.
Conflict of interest statement
Declaration of interest
The authors have no relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript. This includes employment, consultancies, honoraria, stock ownership or options, expert testimony, grants or patents received or pending, or royalties.
Figures
![Figure 1.](https://www.ncbi.nlm.nih.gov/pmc/articles/instance/6355461/bin/nihms-1514617-f0001.gif)
Similar articles
-
Cross-Protection against MERS-CoV by Prime-Boost Vaccination Using Viral Spike DNA and Protein.J Virol. 2020 Nov 23;94(24):e01176-20. doi: 10.1128/JVI.01176-20. Print 2020 Nov 23. J Virol. 2020. PMID: 32967955 Free PMC article.
-
Superior immune responses induced by intranasal immunization with recombinant adenovirus-based vaccine expressing full-length Spike protein of Middle East respiratory syndrome coronavirus.PLoS One. 2019 Jul 22;14(7):e0220196. doi: 10.1371/journal.pone.0220196. eCollection 2019. PLoS One. 2019. PMID: 31329652 Free PMC article.
-
Advances in MERS-CoV Vaccines and Therapeutics Based on the Receptor-Binding Domain.Viruses. 2019 Jan 14;11(1):60. doi: 10.3390/v11010060. Viruses. 2019. PMID: 30646569 Free PMC article. Review.
-
Progress of Middle East respiratory syndrome coronavirus vaccines: a patent review.Expert Opin Ther Pat. 2017 Jun;27(6):721-731. doi: 10.1080/13543776.2017.1281248. Epub 2017 Jan 25. Expert Opin Ther Pat. 2017. PMID: 28121202 Review.
-
Recombinant Receptor-Binding Domains of Multiple Middle East Respiratory Syndrome Coronaviruses (MERS-CoVs) Induce Cross-Neutralizing Antibodies against Divergent Human and Camel MERS-CoVs and Antibody Escape Mutants.J Virol. 2016 Dec 16;91(1):e01651-16. doi: 10.1128/JVI.01651-16. Print 2017 Jan 1. J Virol. 2016. PMID: 27795425 Free PMC article.
Cited by
-
Nucleic acid vaccine candidates encapsulated with mesoporous silica nanoparticles against MERS-CoV.Hum Vaccin Immunother. 2024 Dec 31;20(1):2346390. doi: 10.1080/21645515.2024.2346390. Epub 2024 May 1. Hum Vaccin Immunother. 2024. PMID: 38691025 Free PMC article.
-
An in silico approach to develop potential therapies against Middle East Respiratory Syndrome Coronavirus (MERS-CoV).Heliyon. 2024 Feb 9;10(4):e25837. doi: 10.1016/j.heliyon.2024.e25837. eCollection 2024 Feb 29. Heliyon. 2024. PMID: 38379969 Free PMC article.
-
COVID-19 immunity and vaccines: what a pharmacist needs to know.Asian Biomed (Res Rev News). 2021 Apr 30;15(2):51-67. doi: 10.2478/abm-2021-0008. eCollection 2021 Apr. Asian Biomed (Res Rev News). 2021. PMID: 37551403 Free PMC article. Review.
-
Synthesis and spectroscopic study of novel mixed ligand formula "Artemisinin/Zn" and assessment of its inhibitory effect against "SARS-CoV-2″.Heliyon. 2023 Jun;9(6):e17177. doi: 10.1016/j.heliyon.2023.e17177. Epub 2023 Jun 19. Heliyon. 2023. PMID: 37366527 Free PMC article.
-
A comprehensive insight on the challenges for COVID-19 vaccine: A lesson learnt from other viral vaccines.Heliyon. 2023 Jun;9(6):e16813. doi: 10.1016/j.heliyon.2023.e16813. Epub 2023 Jun 7. Heliyon. 2023. PMID: 37303517 Free PMC article. Review.
References
-
- Zaki AM, van BS, Bestebroer TM, et al. Isolation of a novel coronavirus from a man with pneumonia in Saudi Arabia. N Engl J Med 2012;367(19):1814–20. - PubMed
-
- WHO. Middle East respiratory syndrome coronavirus (MERS-CoV). [cited 2018]. Available from: http://www.who.int/emergencies/mers-cov/en/.
-
- WHO. List of Blueprint priority diseases. [cited 2018]. Available from: http://www.who.int/blueprint/priority-diseases/en/.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources